Key result
FLT1 downregulation delays vascular aging by suppressing MAPK signaling in mice and cell models.
Why the study?
Does downregulation of FLT1 delay vascular aging in vascular smooth muscle cells and mouse models?
Does downregulation of FLT1 delay vascular aging in vascular smooth muscle cells and mouse models?
This preclinical study investigates the role of FLT1 downregulation in delaying vascular aging via the MAPK signaling pathway.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open FLT1 as a therapeutic target for vascular aging pending human studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied Vascular aging. FLT1 downregulation (siRNA) vs. FLT1 overexpression / Control was evaluated on VSMC senescence, cell proliferation, and DNA damage. Downregulation of FLT1 delayed vascular aging by suppressing MAPK signaling pathway activation in vascular smooth muscle cells in vitro and in a mouse model.
Synapse has enriched 10 related papers. Consider them for comparative context: